Expanded access programs (EAPs), have been in and out of the pharmaceutical spotlight since their inception back in the late 1970s. While a formal EA program was first established in 1987 in response to HIV/AIDS, it wasn’t until the 2013 Ebola virus outbreak that the...

Based on our experience of implementing comparator sourcing strategy to meet studies’ increasing complexity, Oximio held a webinar to explore this topic further and provide actionable insight for our participants. Below is a short summary of the questions asked by our...

The number of clinical trials starting in Serbia is returning to pre-pandemic levels, but the context in which these studies are operating has changed. The impact of COVID-19 demonstrated the limitations of the direct-to-site logistics model, when supply chains were...

Cell and gene therapy innovators are scaling up and out to reach more patients. Clinical Trials Arena spoke to the team at Oximio (formerly the SMO Group) to discuss market developments. Most advanced therapy medicinal products (ATMPs, also known as cell and gene...

Over the past two years, Oximio’s operations have been affected by a combination of two factors: organic growth and geographic expansion. Significant organizational expansion has necessitated a comprehensive reconstruction of the human resources area – as...

No one has ever said that running clinical trials is easy. Rather, studies are arguably increasing in complexity due to ever-more sophisticated treatments, globalisation and the sharp rise in trends such as the boom in direct-to-patient (DtP) services. Meanwhile,...

The last 12 months were full of challenges for trial sponsors and the clinical trials market saw dynamic change when the Covid-19 pandemic introduced new logistical problems that had to be confronted and solved rapidly. Now, as the dust begins to settle,...

Transformation is an overused word in the modern business lexicon, so it’s refreshing to hear a business leader, in the midst of what many would consider a legitimate excuse to use the T word, talk instead about continuity and stability....